Cladribine for Untreated or Early Low-Grade Non-Hodgkin's Lymphoma

References

• Christensen L.F., Broom A.D., Robins M.J., Bloch A. Synthesis and biochemical activity selected 2,6-disub-stituted-(2-deoxy-α- and β-D-erythro-pentofuranosyl)purines. J. Med. Chem. 1972; 15: 735–739
   PubMed Web of Science ®Google Scholar
• Carson D.A., Wasson D.B., Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. 1984; 2232–2236
   PubMed Web of Science ®Google Scholar
• J Santana V.M., Hurwitz C.A., Blakley R.L., Crom W.R., Luo X., Roberts W.M., Ribiero R., Mahnoud H., Krance R.A. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84: 1237–1242
   PubMed Web of Science ®Google Scholar
• Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J., Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 334: 9–13
   Web of Science ®Google Scholar
• Piro L.D., Carrera C.J., Carson D.A., Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New. Engl. J. Med. 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Estey E., Kurzrock R., Kantarjian H., O'Brian S., McCredie K., Beran M., Roller C, Keating M., Hirsch-Ginsberg C, Huh Y., Freireich E. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Juliusson G., Heldal D., Hippe E., Hedenus M., Wallman K., Malm C., Stolt C.M., Evensen S.A., Tjønnfjord G., Lenkei R., Liliemark J. Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. 1995; 13: 989–995
   PubMed Web of Science ®Google Scholar
• Piro L.D., Carrera C.J., Beutler E., Carson D.A. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C.J., Carson D., Beutler E.J., Piro L. Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymph. 1991; 5(Suppl)133–138
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia; Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol 1992; 11: 679–689
   Web of Science ®Google Scholar
• Liliemark J., Porwit A., Juliusson G. Intermittent infusion of cladribine in previously treated patients with low-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 1997; 25: 313–318
   PubMed Web of Science ®Google Scholar
• Kay A., Saven A., Carrera C., Carson D., Thurston D., Beutler E., Piro L. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Morton J., Taylor K., Bunce I., Eliadis P., Rentoul A., Moore D., Kelly C., Wright S., Bashford J., Rodwell R., Rooney K., Mulligan S., Firhin F., Doods A., Parkin J., Lowenthal R., Kimber R., Frost T., Grigg A., Goldstein D., Stone J., Lee N. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Br. J. Haematol. 1996; 95: 110–115
   PubMed Web of Science ®Google Scholar
• Bosly A., Ferrant A., Delannoy A., Chatelain P., Martiat G., Cornu G., Doyen C. 2-Chlorodeoxyadenosine therapy in non-Hodgkin's lymphoma. Blood 1993; 10(suppl. 1)560
   Google Scholar
• Liliemark J., Hagberg H., Cavallin-Ståhl E., Juliusson G. Cladribine (2-CdA) for early low grade non-Hodgkin's lymphoma (LG-NHL). Blood 1994; 84(suppl)168a
   Google Scholar
• Liliemark J., Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res. 1991; 51: 5570–5572
   PubMed Web of Science ®Google Scholar
• Liliemark J., Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res. 1995; 1: 385–390
   PubMed Web of Science ®Google Scholar
• Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L., Delsol G., Wolf-Peeters C.D., Falini B., Gatter K.C, Grogan T.M., Isacsson P., Knowles D., Mason D., Muller-Heremlink H., Pileri S., Piris M., Ralfkiear E., Warnke R. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Green S., Weiss G. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Investigational new drugs. 1992; 10: 239–253
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R.H., Kosty M., Beutler E., Piro L.D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol 1995; 13: 570–574
   PubMed Web of Science ®Google Scholar
• Saven A., Emanuele S., Kasty M., Koziol J., Ellison D., Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710–1716
   PubMed Web of Science ®Google Scholar
• Betticher D.C, Zucca E., vonRohr A., Egger T., Radford J.A., Ambrosetti A., Bürki K., Rufener B., Schmitz S.F., Cerny T. 2-chlorodeoxyadenosine (2-CDA) therapy in untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann. Oncol. 1996; 7: 793–799
   PubMed Web of Science ®Google Scholar
• Piro L.D., Petroni G., Barcos M., Johnson J., Saven A., Peterson B. Bolus infusion 2-chlorodeoxyadenosine (2CdA) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL). Blood 1995; 86(suppl. 1)274a
   Google Scholar
• Rummel M., Mitrou P.S., Leimer L., Knuth A., Schadeck-Gressel C, Hossfeld D., Bergmann L., Hoelzer D. 2-Chlorodeoxyadenosine (2-CDA, cladribine) in the treatment of previously untreated low-grade non-Hodgkin's lymphomas-preliminary results of a phase II study. Proc. Am. Soc. Clin. Oncol 1997; 16: 18a
   Google Scholar
• Kaufmann T., Coleman M., Pasmantier M. Purine analog (PA) therapy for untreated mantle cell (MCL) and monocytoid (MNL) lymphomas: immunophenotype does not predict response to fludarabine (FLUD) and cladribine (2CdA). Pre. Am. Soc. Clin. Oncol 1996; 15: 1320
   Google Scholar
• Kimby E., Björkholm M., Gahrton G., Glimelius B., Hagberg H., Johansson B., Johansson H., Juliusson G., Järnmark M., Löfvenbergi E. Chlorambucil/prednisolone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann. Oncol 1994; 5(suppl. 2)67–71
   Google Scholar
• Cheson B.D. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol 1995; 13: 2431–2448
   PubMed Web of Science ®Google Scholar
• vandenNeste E., Delannoy A., Vandercam B., Bosly A., Ferrant A., Mineur P., Montfort L., Martiat P., Straetmans N., Filleul B., Michaux J.L. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol 1996; 56: 235–240
   PubMed Web of Science ®Google Scholar
• vonRohr A., Betticher D.C, Fey M.F., Racine C, Tobler A., Cerney T. Treatment with combined 2-chlorodeoxyadenosine and interleukin-2 for low-grade B cell malignancies: a pilot study. Proc. Am. Soc. Clin. Oncol 1997; 16: 18a
   Google Scholar
• Juliusson G., Lenkei R., Liliemark J. Flow cytometry of blood and bone marrow eels from patients with hairy cell leukemia. Phenotype of hairy cells and lymphocyte subsets following treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672–3681
   PubMed Web of Science ®Google Scholar